Ambeed.cn

首页 / / / / Ceruletide

雨蛙素 /Ceruletide {[allProObj[0].p_purity_real_show]}

货号:A569478 同义名: Cerulein;Caerulein

Ceruletide 是一种十肽,也是一种有效的胆囊收缩素受体激动剂。Ceruletide 是一种安全且有效的促胆囊收缩剂,具有直接作用于胆囊肌肉和胆管的痉挛效应。

Ceruletide 化学结构 CAS号:17650-98-5
Ceruletide 化学结构
CAS号:17650-98-5
Ceruletide 3D分子结构
CAS号:17650-98-5
Ceruletide 化学结构 CAS号:17650-98-5
Ceruletide 3D分子结构 CAS号:17650-98-5
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

Ceruletide 纯度/质量文件 产品仅供科研

货号:A569478 标准纯度: {[allProObj[0].p_purity_real_show]}
批次查询: 批次纯度:

全球学术期刊中引用的产品

Cell Host Microbe, 2024. Ambeed. [ A163338 ]
Cancer Res., 2024. Ambeed. [ A295334 ]
J. Pharm. Investig., 2024. Ambeed. [ A221527 , A691302 , A272538 , A187261 ]
J. Fungi, 2024, 10(11): 751. Ambeed. [ A796919 ]
JBC, 2024, 107935. Ambeed. [ A194396 ]
更多 >

Ceruletide 生物活性

描述 Cholecystokinin octapeptide (cholecystokinin-8) is found in the peripheral tissue and central nervous system (CNS). It is becoming clear that cholecystokinin-8 sulphate may function as a neurotransmitter or neuromodulator in the CNS. Thus, cholecystokinin-8 sulphate is released from synaptic vesicles in a calcium-dependent manner, binds to specific high affinity cholecystokinin receptors and exerts primarily excitatory effect on CNS neurons. One potential role that has been proposed for cholecystokinin is the modulation of central opiate nociceptive mechanism. Cholecystokinin receptors are generally divided into two classes, cholecystokinin-A (alimentary) and cholecystokin- in-B (brain)[3]. Caerulein is a decapeptide isolated from frog skin, which has been shown to possess the same biological and pharmacological activities as cholecystokinin-8[3]. Ceruletide in supramaximal but not in physiological doses activated NF-kappaB/Rel in vitro. This activation might induce a self-defending genetic program before the onset of cellular injury, which might prevent higher degrees of damage of pancreatic acinar cells after secretagogue hyperstimulation[4]. Ceruletide serum bile acid (SBA) stimulation circumvented exogenous and endogenous influences associated with postprandial (PP) SBA stimulation. Ceruletide SBA stimulation might perform as well as PP SBA stimulation in dogs with portosystemic shunt (PSS) and be more sensitive for the detection of hepatic dysfunction in dogs with upper respiratory disease (URD)[5]. Ceruletide (0.4-0.5 mcg/kg, i.v.; 3-4 mcg/kg, s.c.) resulted in emesis and evacuation of the bowel in the intact conscious dog, and recovery was complete 15 - 30 min after i. v. administration and 2 - 4h after s.c. administration. Ceruletide (5 - 15 ng/kg, i.v.) showed a marked spasmogenic effect on the pylorus of rats. Ceruletide also reduced blood pressure in anesthetized dogs[6].

Ceruletide 动物研究

Dose Mice: 1 μg/kg - 300 μg/kg[3] (i.p.); 0.01 mg/kg - 0.1 mg/kg[4] (s.c.)
Administration i.p.

Ceruletide 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT03748667 - Not yet recruiting December 2020 United States, California ... 展开 >> San Francisco Veterans Affairs Medical Center. University of California Not yet recruiting San Francisco, California, United States, 94121 Contact       endoresection@me.com    Principal Investigator: Tonya Kaltenbach          United States, North Carolina University of North Carolina Not yet recruiting Chapel Hill, North Carolina, United States, 27599 Contact       mcgills@email.unc.edu    Principal Investigator: Sarah McGill          Japan National Cancer Center Not yet recruiting Tokyo, Japan, 104-0045 Contact       tasakamo529@gmail.com    Principal Investigator: Taku Sakamoto          Spain Hospital Clínico Universitario Lozano Blesa Not yet recruiting Zaragoza, Aragón, Spain, 50009 Contact       angel.ferrandez@telefonica.net    Principal Investigator: Ángel Ferrández          Hospital Universitari Germans Trias i Pujol (Can Ruti) Not yet recruiting Badalona, Cataluña, Spain, 08916 Contact       hugoikuo@gmail.com    Principal Investigator: Hugo Uchima          Hospital Clínic de Barcelona Not yet recruiting Barcelona, Cataluña, Spain, 08036 Contact       MPELLISE@clinic.cat    Principal Investigator: Maria Pellisé          Sub-Investigator: Miriam Cuatrecasas          Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Not yet recruiting Barcelona, Cataluña, Spain, 08036 Contact       JCAMPS@clinic.cat    Sub-Investigator: Jordi Camps          Althaia. Xarxa Assistencial Universitària de Manresa Not yet recruiting Manresa, Cataluña, Spain, 08243 Contact       orosinol@althaia.cat    Sub-Investigator: Òria Rosiñol          Hospital Universitario y Politécnico de La Fe Not yet recruiting Valencia, Comunidad Valenciana, Spain, 46009 Contact       mbustamantebalen@gmail.com    Principal Investigator: Marco Bustamante          Complejo Hospitalario de Navarra Not yet recruiting Pamplona, Navarra, Spain, 31008 Contact       edualbeniz@hotmail.com    Principal Investigator: Eduardo Albéniz          Hospital Ramón y Cajal Not yet recruiting Madrid, Spain, 28034 Contact       enrodesan@gmail.com    Principal Investigator: Enrique Rodríguez          Hospital 12 de Octubre Not yet recruiting Madrid, Spain, 28041 Contact       josecarlos.marin@salud.madrid.org    Principal Investigator: José Carlos Marín 收起 <<
NCT01491178 - Completed - -
NCT02808403 - Recruiting April 30, 2022 -

Ceruletide 参考文献

[1]Furuyama T, Tanaka S, et al. Proteasome activity is required for the initiation of precancerous pancreatic lesions. Sci Rep. 2016 May 31;6:27044.

[2]Pradel P, Estival A, et al. Caerulein and gastrin(2-17 ds) regulate differently synthesis of secretory enzymes, mRNA levels and cell proliferation in pancreatic acinar cells (AR4-2J). Biochem J. 1993 Feb 15;290 ( Pt 1):219-24.

[3]Zarrindast MR, Malekzadeh A, Rezayat M, Ghazi-Khansari M. Effects of cholecystokinin receptor agonist and antagonists on morphine dependence in mice. Pharmacol Toxicol. 1995 Dec;77(6):360-4. doi: 10.1111/j.1600-0773.1995.tb01042.x. PMID: 8835359.

[4]Steinle AU, Weidenbach H, Wagner M, Adler G, Schmid RM. NF-kappaB/Rel activation in cerulein pancreatitis. Gastroenterology. 1999 Feb;116(2):420-30. doi: 10.1016/s0016-5085(99)70140-x. PMID: 9922324.

[5]Bridger N, Glanemann B, Neiger R. Comparison of postprandial and ceruletide serum bile acid stimulation in dogs. J Vet Intern Med. 2008 Jul-Aug;22(4):873-8. doi: 10.1111/j.1939-1676.2008.0114.x. PMID: 18537882.

[6]Vincent ME, Wetzner SM, Robbins AH. Pharmacology, clinical uses, and adverse effects of ceruletide, a cholecystokinetic agent. Pharmacotherapy. 1982 Jul-Aug;2(4):223-34. doi: 10.1002/j.1875-9114.1982.tb03189.x. PMID: 6763205.

Ceruletide 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

0.74mL

0.15mL

0.07mL

3.70mL

0.74mL

0.37mL

7.39mL

1.48mL

0.74mL

Ceruletide 技术信息

CAS号17650-98-5
分子式C58H73N13O21S2
分子量 1352.405
别名 Cerulein;Caerulein;CCRIS-3063;FI-6934
运输蓝冰
存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Sealed in dry,Store in freezer, under -20°C

溶解度

DMSO: 105 mg/mL(77.64 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

H2O: 2.5 mg/mL(1.85 mM),配合低频超声助溶

DMF: 15 mg/mL(11.09 mM),配合低频超声助溶

动物实验配方
Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。